Integrum AB: Invitation to the Second Quarter 2024/25 Results Presentation
Mölndal, Sweden – November 29, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its second quarter 2024/25 results on December 4, 2024 at 14:00 CEST.
Integrum’s CEO Scott Flora will present the report together with CFO Jörgen Svanström in a webcast. The presentation will be held in English.
Time: Wednesday, December 4, 2024 at 14:00 CEST.
Location: Webcast (see link below).
The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/
The webcast and presentation material will be accessible via https://www.finwire.tv/webcast/integrum/q2-2024/ where it is also possible to ask questions.
For more information,
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.
About Integrum
Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. OPRA® Implant System is a registered trademark of Integrum AB in the European Union.
To learn more, please visit https://integrum.se/.